CClinicalTrials.gg
CompletedNCT05591573Updated Mar 12, 2024

The Impact of Glycemic Index on Sleep and Memory Consolidation

An interventional study of Low glycemic index drink and High glycemic index drink in Sleep Architecture, Cognitive Function and Mood, sponsored by Swansea University. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Swansea University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

The study will test whether the consumption of a low versus a high glycemic index pre-bed drink influences sleep architecture, memory consolidation, nocturnal glucose metabolism, and mood.

Read the detailed description

Few studies have examined the impact of meal composition on sleep. Most research has focused on carbohydrate intake, although reports are sporadic and confounded by the manipulation of other macronutrients. Nonetheless, the pattern of results appears to depend on the nature of the sleep variable under investigation e.g., latency, duration, or efficiency. The study will determine whether manipulating the glycemic index of a pre-bed drink influences sleep architecture, procedural and declarative memory consolidation, nocturnal glucose metabolism, and mood.

Participants will stay in the sleep laboratory for three nights, each night separated by one week (visit 1, 2, and 3). The first night is an acclimatisation night. The same procedure will be followed on all three nights, as described below.

On the morning of each visit, a continuous glucose monitor will be set up and worn until 8pm the following evening. Participants will be asked to return to the sleep laboratory at 7pm, having fasted for five hours, and asked to consume a standardised evening meal. Several mood questionnaires will be completed throughout the evening and a polysomnography will be set up. Two memory tasks will be administered at approximately 10pm. Immediately after this, participants will consume either water (night 1), or a low glycemic index or high glycemic index drink (night 2 or 3). Participants will retire to bed at approximately 11pm and woken up between 6.30am - 8am, depending on personal preference.

In the morning, the memory tasks will be administered again, as well as two mood questionnaires. Participants will be asked to wear a Pro-Diary watch throughout the day, which measures mood and hunger. At 8pm, both the continuous glucose monitor and Pro-diary watch will be collected from the participant.

02

Conditions studied

  • Sleep Architecture
  • Cognitive Function
  • Mood
  • Glucose Metabolism
03

In context

Lead sponsor

Swansea University is the lead sponsor of 40 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male (given that the menstrual cycle may influence sleep polysomnography)
  • Good health
  • Not taking any medication known to effect sleep or metabolism
  • Normal sleep duration (i.e. between 6.5 - 9 hours of sleep per night)
  • A sleep efficiency score above 80% (Pittsburg Sleep Quality Index)
  • Normal sleep schedule (i.e. fall asleep between 10pm and 12pm)
  • No difficulty sleeping in new places

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any physical or mental disorder e.g. diabetes, cardiovascular disorders, gastrointestinal disorders, sleep problems, epilepsy, or mood disorders
  • Unhealthy weight (BMI over 30)
  • Drink more than 300mg of caffeine per day (3 - 4 standard sized 8-oz cups)
  • Work nights or shifts
  • Smoke/vape
  • Regularly drink alcohol (>3 glasses per day)
  • Used recreational drugs within the last 6 months
  • Take part in >3 hours of vigorous exercise per week
  • Any known food allergies or intolerances
  • Nocturnal eating or regular consumption of alcohol before bed (assessed by the Meal Pattern Questionnaire)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Low glycemic index drink

    Fruit drink containing low glycemic index sugar.

    Dietary Supplement: Low glycemic index drink

  • Experimental
    High glycemic index drink

    Fruit drink containing high glycemic index sugar.

    Dietary Supplement: High glycemic index drink

Interventions

  • Dietary supplementLow glycemic index drink

    Fruit flavoured drink with low glycemic index sugar (300 ml)

  • Dietary supplementHigh glycemic index drink

    Fruit flavoured drink with high glycemic index sugar (300 ml)

06

What researchers measure

Primary outcomes

  1. Sleep onset latency (polysomnography)

    Onset of sleep from the time the lights are turned off.

    Time frame: Bedtime (approx. 11.00pm) to wake time (approx 7.30am)

  2. Total sleep time (polysomnography)

    The total number of hours of sleep.

    Time frame: Bedtime (approx. 11.00pm) to wake time (approx 7.30am)

  3. Wake after sleep onset (polysomnography)

    Hours of wake time after three epochs of sleep have occurred.

    Time frame: Bedtime (approx. 11.00pm) to wake time (approx 7.30am)

  4. Sleep efficiency (polysomnography)

    Total sleep time divided by the time from lights out until awakening in the morning.

    Time frame: Bedtime (approx. 11.00pm) to wake time (approx 7.30am)

  5. Sleep stages (polysomnography)

    Time spent in each sleep stage.

    Time frame: Bedtime (approx. 11.00pm) to wake time (approx 7.30am)

  6. Arousal index (polysomnography)

    Number of arousals throughout the night.

    Time frame: Bedtime (approx. 11.00pm) to wake time (approx 7.30am)

  7. Leeds Sleep Evaluation Questionnaire

    Subjective assessment of sleep quality. Scores range from 0 to 30. Higher scores indicate poorer sleep quality.

    Time frame: Administered 10 - 20 minutes after waking up in the morning,

Secondary outcomes

  1. Glucose response (continuous glucose monitor)

    The 2h and 3h incremental area under the curve (iAUC) will be used to assess glycemic response to the pre-bed drink. The mean amplitude of glycemic excursion (MAGE) will be assessed as an indicator for glycemic variability during the night and for 25 hours.

    Time frame: 25 hours during night 2 and night 3 (weeks 2 and 3)

  2. Finger tapping task (procedural memory)

    The change in performance from the learning phase to the recall phase.

    Time frame: Completed at 10pm, and between 6.30 - 8am the following morning, on night 2 and night 3 (week 2 and 3).

  3. Story recall task (declarative memory)

    The number of content words (nouns, adjectives, and verbs) correctly recalled.

    Time frame: Completed at 10pm, and between 6.30 - 8am the following morning, on night 2 and night 3 (week 2 and 3).

  4. Epworth Sleepiness Scale

    Subjective assessment of daytime sleepiness. Scores range from 0 - 24. Higher scores indicate more daytime sleepiness.

    Time frame: Administered at 8pm on the evening after night 2 and night 3 (week 2 and 3).

  5. Mood and hunger

    Scores range from 0 - 100. Higher scores indicate stronger feelings.

    Time frame: Completed five times throughout the evening and twice in the morning (immediately after waking up and 20-30 minutes later) on night 2 and night 3 (week 2 and 3). .

  6. Mood

    Pro-diary watch

    Time frame: Prompted from 9.30am - 5.30pm after night 2 and night 3 (week 2 and 3).

  7. Actigraphy

    Time spent in each sleep stage.

    Time frame: Night 2 and night 3 (week 2 and 3).

07

Study locations

1 site
  • Swansea University
    Swansea, West Glamorgan SA2 8PP, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05591573
Lead sponsor
Swansea University
Responsible party
Dr Hayley Young (Associate Professor, Swansea University) — Principal investigator
First posted
Oct 24, 2022
Start date
Dec 31, 2022
Primary completion
Apr 30, 2023
Completion
Apr 30, 2023
Last update
Mar 12, 2024

Study contacts

Hayley Young
study director · Swansea University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion